Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 1
1997 1
1998 4
2000 1
2003 3
2004 2
2005 5
2006 4
2007 5
2008 4
2009 1
2010 2
2011 4
2012 2
2013 5
2014 4
2015 3
2016 2
2017 1
2018 2
2019 5
2020 6
2021 5
2022 1
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Marks ZRC, Campbell NK, Mangan NE, Vandenberg CJ, Gearing LJ, Matthews AY, Gould JA, Tate MD, Wray-McCann G, Ying L, Rosli S, Brockwell N, Parker BS, Lim SS, Bilandzic M, Christie EL, Stephens AN, de Geus E, Wakefield MJ, Ho GY, McNally O; Australian Ovarian Cancer Study; McNeish IA, Bowtell DDL, de Weerd NA, Scott CL, Bourke NM, Hertzog PJ. Marks ZRC, et al. Among authors: wakefield mj. Nature. 2023 Aug;620(7976):1063-1070. doi: 10.1038/s41586-023-06421-w. Epub 2023 Aug 16. Nature. 2023. PMID: 37587335
Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G, Vandenberg CJ, Nesic K, Ratnayake G, Zhu W, Vissers JHA, Bedő J, Penington J, Wakefield MJ, Kee D, Carmagnac A, Lim R, Shield-Artin K, Milesi B, Lobley A, Kyran EL, O'Grady E, Tram J, Zhou W, Nugawela D, Stewart KP, Caldwell R, Papadopoulos L, Ng AP, Dobrovic A, Fox SB, McNally O, Power JD, Meniawy T, Tan TH, Collins IM, Klein O, Barnett S, Olesen I, Hamilton A, Hofmann O, Grimmond S, Papenfuss AT, Scott CL, Barker HE. Dall G, et al. Among authors: wakefield mj. J Exp Clin Cancer Res. 2023 May 4;42(1):112. doi: 10.1186/s13046-023-02687-0. J Exp Clin Cancer Res. 2023. PMID: 37143137 Free PMC article.
Diverse mechanisms of PARP inhibitor resistance in ovarian cancer.
Wakefield MJ, Nesic K, Kondrashova O, Scott CL. Wakefield MJ, et al. Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188307. doi: 10.1016/j.bbcan.2019.08.002. Epub 2019 Aug 2. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31381953 Review. No abstract available.
Therapeutic options for mucinous ovarian carcinoma.
Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Bowtell DDL, Christie M, Chiew YE, Churchman M, DeFazio A, Fereday S, Gilks CB, Gourley C, Hadley AM, Hendley J, Hunter SM, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Pyman J, Rowley SM, Salazar C, Saunders H, Semple T, Stephens AN, Thio N, Torres MC, Traficante N, Zethoven M, Antill YC, Campbell IG, Scott CL. Gorringe KL, et al. Among authors: wakefield mj. Gynecol Oncol. 2020 Mar;156(3):552-560. doi: 10.1016/j.ygyno.2019.12.015. Epub 2020 Jan 2. Gynecol Oncol. 2020. PMID: 31902686 Free PMC article.
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV; Scottish Genomes Partnership; Cooke SL, Ratnayake G, McNally O, Traficante N; Australian Ovarian Cancer Study12,13; DeFazio A, Weroha SJ, Bowtell DD, McNeish IA, Papenfuss AT, Scott CL, Barker HE. Ho GY, et al. Among authors: wakefield mj. Cancer Res. 2022 Dec 2;82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012. Cancer Res. 2022. PMID: 36206301 Free PMC article.
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K, Krais JJ, Vandenberg CJ, Wang Y, Patel P, Cai KQ, Kwan T, Lieschke E, Ho GY, Barker HE, Bedo J, Casadei S, Farrell A, Radke M, Shield-Artin K, Penington JS, Geissler F, Kyran E, Zhang F, Dobrovic A, Olesen I, Kristeleit R, Oza A, Ratnayake G, Traficante N; Australian Ovarian Cancer Study; DeFazio A, Bowtell DDL, Harding TC, Lin K, Swisher EM, Kondrashova O, Scott CL, Johnson N, Wakefield MJ. Nesic K, et al. Among authors: wakefield mj. medRxiv [Preprint]. 2023 Aug 28:2023.03.20.23287465. doi: 10.1101/2023.03.20.23287465. medRxiv. 2023. PMID: 36993400 Free PMC article. Preprint.
FokI-dCas9 mediates high-fidelity genome editing in pigs.
Fisicaro N, Salvaris EJ, Philip GK, Wakefield MJ, Nottle MB, Hawthorne WJ, Cowan PJ. Fisicaro N, et al. Among authors: wakefield mj. Xenotransplantation. 2020 Jan;27(1):e12551. doi: 10.1111/xen.12551. Epub 2019 Aug 12. Xenotransplantation. 2020. PMID: 31407391
73 results